Literature DB >> 20600502

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.

Toon Stegmann1, Tobias Kamphuis, Tjarko Meijerhof, Ellen Goud, Aalzen de Haan, Jan Wilschut.   

Abstract

Respiratory syncytial virus (RSV) causes severe respiratory disease in children and the elderly. There is no registered RSV vaccine. Early experimental non-replicating vaccines have been found to exacerbate RSV symptoms upon infection causing enhanced respiratory disease. Here we show that immunization of mice with reconstituted virosomes produced from RSV envelopes and containing the lipopeptide adjuvant (P3CSK4), induces high-titer virus-neutralizing antibodies, and the secretion of IFN-gamma through both MHC-I and MHC-II presentation of antigen, with a balanced Th1/Th2 profile. Immunization with RSV virosomes provides sterilizing immunity to virus challenge in mice and cotton rats, while not producing symptoms of enhanced disease. Therefore, these virosomes represent a promising candidate inactivated RSV vaccine formulation. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20600502     DOI： 10.1016/j.vaccine.2010.06.041

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  17 in total

1.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

Review 2.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 3.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

4.  A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Authors:  Marian Alexander Wiegand; Gianni Gori-Savellini; Claudia Gandolfo; Guido Papa; Christine Kaufmann; Eva Felder; Alessandro Ginori; Maria Giulia Disanto; Donatella Spina; Maria Grazia Cusi
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 5.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

6.  A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.

Authors:  Dennis M Lindell; Susan B Morris; Maria P White; Lara E Kallal; Phillip K Lundy; Tarek Hamouda; James R Baker; Nicholas W Lukacs
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

7.  Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.

Authors:  Tobias Kamphuis; Tjarko Meijerhof; Toon Stegmann; Julia Lederhofer; Jan Wilschut; Aalzen de Haan
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

Review 8.  Respiratory syncytial virus: current progress in vaccine development.

Authors:  Rajeev Rudraraju; Bart G Jones; Robert Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Viruses       Date:  2013-02-05       Impact factor: 5.048

9.  Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.

Authors:  Muhammad Shafique; Tjarko Meijerhof; Jan Wilschut; Aalzen de Haan
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

10.  Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Authors:  Patricia A Jorquera; Youngjoo Choi; Katie E Oakley; Thomas J Powell; James G Boyd; Naveen Palath; Lia M Haynes; Larry J Anderson; Ralph A Tripp
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.